BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chlibek R, Smetana J, Sosovickova R, Gal P, Dite P, Stepanova V, Pliskova L, Plisek S. Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening. PLoS One 2017;12:e0175525. [PMID: 28406947 DOI: 10.1371/journal.pone.0175525] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Souda S, Mwita JC, Cainelli F, Mannathoko NB, Anderson M, Moyo S. Seroprevalence and risk factors of hepatitis B, C and D virus infection amongst patients with features of hepatitis in a referral hospital in Botswana: A cross-sectional study. Southern African Journal of Infectious Diseases 2021;36. [DOI: 10.4102/sajid.v36i1.275] [Reference Citation Analysis]
2 Sperle I, Nielsen S, Gassowski M, Naneva Z, Perchemlieva T, Amato-Gauci A, An der Heiden M, Bremer V, Golkocheva-Markova E, Hristov K, Kaneva E, Simeonova Y, Tenev T, Varleva T, Duffell E, Zimmermann R. Prevalence of hepatitis C in the adult population of Bulgaria: a pilot study. BMC Res Notes 2020;13:326. [PMID: 32635926 DOI: 10.1186/s13104-020-05158-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Han R, Zhou J, François C, Toumi M. Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update. BMC Infect Dis 2019;19:655. [PMID: 31337339 DOI: 10.1186/s12879-019-4284-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
4 Flisiak R, Frankova S, Grgurevic I, Hunyady B, Jarcuska P, Kupčinskas L, Makara M, Simonova M, Sperl J, Tolmane I, Vince A, Zarębska-Michaluk D. How close are we to hepatitis C virus elimination in Central Europe? Clin Exp Hepatol 2020;6:1-8. [PMID: 32166117 DOI: 10.5114/ceh.2020.93049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Muhamad NA, Ab Ghani RM, Abdul Mutalip MH, Muhammad EN, Mohamad Haris H, Mohd Zain R, Abdullah N, Muhammad Azami NA, Abd Jalal N, Ismail N, Mhd Yusuf NA, Othman R, Kamalul Arifin AS, Abdullah MS, Kamaruddin MA, Abu Hassan MR, Aris T, Jamal R. Seroprevalence of hepatitis B virus and hepatitis C virus infection among Malaysian population. Sci Rep 2020;10:21009. [PMID: 33273475 DOI: 10.1038/s41598-020-77813-5] [Reference Citation Analysis]
6 Bielen R, Kremer C, Koc ÖM, Busschots D, Hendrickx DM, Vanelderen P, Hens N, Nevens F, Robaeys G. Screening for hepatitis C at the emergency department: Should babyboomers also be screened in Belgium? Liver Int 2019;39:667-75. [PMID: 30525269 DOI: 10.1111/liv.14016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
7 Wei Q, Guo JS. Developing natural marine products for treating liver diseases. World J Clin Cases 2022; 10(8): 2369-2381 [DOI: 10.12998/wjcc.v10.i8.2369] [Reference Citation Analysis]
8 Li Y, Zhao L, Geng N, Zhu W, Liu H, Bai H. Prevalence and characteristics of hepatitis C virus infection in Shenyang City, Northeast China, and prediction of HCV RNA positivity according to serum anti-HCV level: retrospective review of hospital data. Virol J 2020;17:36. [PMID: 32178702 DOI: 10.1186/s12985-020-01316-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Sperl J, Frankova S, Kreidlova M, Merta D, Tothova M, Spicak J. Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis. Ther Clin Risk Manag 2017;13:733-8. [PMID: 28790832 DOI: 10.2147/TCRM.S133983] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
10 Skladaný L, Oltman M, Fraňková S, Dražilová S, Husa P, Šperl J, Hejda V, Urbánek P, Adamcová-Selčanová S, Janičko M, Kristian P, Kupčová V, Rác M, Schréter I, Virág L, Liptáková A, Ondrášová M, Jarčuška P. Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics. Int J Public Health 2020;65:1723-35. [PMID: 33040165 DOI: 10.1007/s00038-020-01496-y] [Reference Citation Analysis]
11 Mason LMK, Veldhuijzen IK, Duffell E, van Ahee A, Bunge EM, Amato-Gauci AJ, Tavoschi L. Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA: A systematic review. J Viral Hepat 2019;26:1431-53. [PMID: 31332919 DOI: 10.1111/jvh.13182] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
12 Sperle I, Nielsen S, Bremer V, Gassowski M, Brummer-Korvenkontio H, Bruni R, Ciccaglione AR, Kaneva E, Liitsola K, Naneva Z, Perchemlieva T, Spada E, Toikkanen SE, Amato-Gauci AJ, Duffell E, Zimmermann R. Developing and Piloting a Standardized European Protocol for Hepatitis C Prevalence Surveys in the General Population (2016-2019). Front Public Health 2021;9:568524. [PMID: 34123980 DOI: 10.3389/fpubh.2021.568524] [Reference Citation Analysis]
13 Gomide GPM, Melo CB, Santos VDS, Salge VD, Camargo FC, Pereira GA, Cabral SCO, Molina RJ, Oliveira CDCHB. Epidemiological survey of hepatitis C in a region considered to have high prevalence: the state of Minas Gerais, Brazil. Rev Soc Bras Med Trop 2019;52:e20190202. [PMID: 31596352 DOI: 10.1590/0037-8682-0202-2019] [Reference Citation Analysis]
14 Shady NH, Khattab AR, Ahmed S, Liu M, Quinn RJ, Fouad MA, Kamel MS, Muhsinah AB, Krischke M, Mueller MJ, Abdelmohsen UR. Hepatitis C Virus NS3 Protease and Helicase Inhibitors from Red Sea Sponge (Amphimedon) Species in Green Synthesized Silver Nanoparticles Assisted by in Silico Modeling and Metabolic Profiling. Int J Nanomedicine 2020;15:3377-89. [PMID: 32494136 DOI: 10.2147/IJN.S233766] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
15 Frankova S, Jandova Z, Jinochova G, Kreidlova M, Merta D, Sperl J. Therapy of chronic hepatitis C in people who inject drugs: focus on adherence. Harm Reduct J 2021;18:69. [PMID: 34193156 DOI: 10.1186/s12954-021-00519-y] [Reference Citation Analysis]
16 Li CW, Yang CJ, Sun HY, Tsai MS, Lin SP, Lin TY, Cheng CY, Lee YC, Huang YS, Liu CE, Lee YT, Tang HJ, Wang NC, Cheng SH, Ko WC, Hung CC; Taiwan HIV Study Group. Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan. PLoS One 2018;13:e0194149. [PMID: 29547628 DOI: 10.1371/journal.pone.0194149] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]